Sökning: onr:"swepub:oai:DiVA.org:uu-471026" >
A single low dose o...
A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania
-
- Mwaiswelo, Richard Owden (författare)
- Trop Pesticides Res Inst, Dept Res & Training, Arusha, Tanzania.;Hubert Kairuki Mem Univ, Dept Microbiol Immunol & Parasitol, Dar Es Salaam, Tanzania.;Muhimbili Univ Hlth & Allied Sci, Dept Med Parasitol & Entomol, Dar Es Salaam, Tanzania.
-
- Ngasala, Billy (författare)
- Uppsala universitet,Internationell barnhälsa och nutrition,Muhimbili Univ Hlth & Allied Sci, Dept Med Parasitol & Entomol, Dar Es Salaam, Tanzania.
-
- Msolo, Dominick (författare)
- Univ Dar Es Salaam, Coll Nat & Appl Sci, Dar Es Salaam, Tanzania.
-
visa fler...
-
- Kweka, Eliningaya (författare)
- Trop Pesticides Res Inst, Dept Res & Training, Arusha, Tanzania.
-
- Mmbando, Bruno P. (författare)
- Natl Inst Med Res, Tanga Res Ctr, Tanga, Tanzania.
-
- Mårtensson, Andreas, 1963- (författare)
- Uppsala universitet,Internationell barnhälsa och nutrition
-
visa färre...
-
Trop Pesticides Res Inst, Dept Res & Training, Arusha, Tanzania;Hubert Kairuki Mem Univ, Dept Microbiol Immunol & Parasitol, Dar Es Salaam, Tanzania.;Muhimbili Univ Hlth & Allied Sci, Dept Med Parasitol & Entomol, Dar Es Salaam, Tanzania. Internationell barnhälsa och nutrition (creator_code:org_t)
- 2022-03-12
- 2022
- Engelska.
-
Ingår i: Malaria Journal. - : Springer Nature. - 1475-2875. ; 21
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Primaquine is a pro-drug and its active metabolite is potent against mature Plasmodium falciparum gametocytes. Primaquine is metabolized by a highly polymorphic cytochrome P450 2D6 (CYP2D6) enzyme. Mutations in the gene encoding this enzyme may lead to impaired primaquine activity. This study assessed if 0.25 mg/kg single-dose primaquine is safe and sufficient to reduce transmission of gametocytes in individuals with no, reduced, or increased CYP2D6 enzyme activity.Methods: Between June 2019 and January 2020 children aged 1-10 years, attending at Yombo dispensary, Bagamoyo district, with confirmed microcopy-determined uncomplicated P. falciparum malaria were enrolled in the study. The enrolled patients were treated with a standard artemether-lumefantrine regimen plus 0.25 mg/kg single-dose primaquine and followed up for 28 days for clinical and laboratory assessment. Primaquine was administered with the first dose of artemether-lumefantrine. Safety assessment involved direct questioning and recording of the nature and incidence of clinical signs and symptoms, and measurement of haemoglobin (Hb) concentration. Blood samples collected from 100 patients were used for assessment of post-treatment infectiousness on day 7 using mosquito membrane feeding assays. Molecular methods were used to determine CYP2D6 and glucose-6-phosphate dehydrogenase (G6PD) status. The primary outcome was the safety of 0.25 mg/kg single-dose primaquine based on CYP2D6 status.Results: In total, 157 children [median age 6.4 (Interquartile range 4.0-8.2) years] were recruited, of whom 21.0% (33/157) and 12.7% (20/157) had reduced CYP2D6 and deficient G6PD activity, respectively. Day 3 mean absolute Hb concentration reduction was 1.50 g/dL [95% confidence interval (CI) 1.10-1.90] and 1.51 g/dL (95% CI 1.31-1.71) in reduced and normal CYP2D6 patients, respectively (t = 0.012, p = 0.990). The day 3 mean absolute Hb concentration reduction in G6PD deficient, G6PD normal and heterozygous female was 1.82 g/dL (95% CI 1.32-2.32), 1.48 g/dL (95% CI 1.30-1.67) and 1.47 g/dL (95% CI 0.76-2.18), respectively (F = 0.838, p = 0.435). Sixteen percent (16/98) of the patients each infected at least one mosquito on day 7, and of these, 10.0% (2/20) and 17.9% (14/78) had reduced and normal CYP2D6 enzyme activity, respectively (x(2) = 0.736, p = 0.513).Conclusion: Single-dose 0.25 mg/kg primaquine was safe and sufficient for reducing transmission of P. falciparum gametocytes regardless of CYP2D6 or G6PD status. Trial registration Study registration number: NCT03352843.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Nyckelord
- Safety
- Efficacy
- Single low-dose primaquine
- Plasmodium falciparum gametocytes
- G6PD deficiency
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas